Skip to main content

Advertisement

Table 3 Risk of reduced overall survival by plasma levels of C-reactive protein and prognostic factors

From: Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study

     Tertiles of C-reactive protein (mg/L)  
Stratification No. of patients No. of deaths P, inter-action 1st (<1.04) 2nd (1.04 to 3.24) 3rd (>3.24) P, trend
     Multifactor-adjusted hazard ratio (95% CI)  
None 2,910 383   1.0 1.29 (0.96 to 1.72) 1.84 (1.39 to 2.45) <0.001
Age at diagnosis        
   <57 years 964 74 0.40 1.0 0.97 (0.49 to 1.90) 1.69 (0.91 to 3.14) 0.08
   57 to 69 years 964 103   1.0 1.76 (0.99 to 3.11) 2.53 (1.42 to 4.50) 0.002
   ≥69 years 982 206   1.0 1.18 (0.78 to 1.79) 1.59 (1.07 to 2.37) 0.01
Tumour size        
   ≤20 mm 1,501 119 0.33 1.0 1.02 (0.62 to 1.68) 1.66 (1.03 to 2.68) 0.03
   20 to 50 mm 1,409 264   1.0 1.48 (1.02 to 2.15) 2.04 (1.41 to 2.95) <0.001
   >50 mm 103 23   1.0 2.74 (0.36 to 20.7) 0.63 (0.06 to 6.61) 0.44
Lymph node status        
   Lymph node negative 1,334 132 0.59 1.0 1.07 (0.65 to 1.76) 1.48 (0.92 to 2.38) 0.08
   Lymph node positive 1,335 191   1.0 1.55 (1.01 to 2.38) 2.04 (1.33 to 3.12) 0.001
Distant metastases        
   No 2,780 343 0.66 1.0 1.31 (0.96 to 1.78) 1.80 (1.33 to 2.44) <0.001
   Yes 40 23   1.0 0.50 (0.01 to 21.0) 15.6 (1.10 to 221) 0.03
Tumour grade        
   Well differentiated 685 50 0.69 1.0 0.74 (0.31 to 1.75) 1.49 (0.68 to 3.28) 0.21
   Moderately differentiated 1,262 154   1.0 1.17 (0.74 to 1.88) 1.78 (1.14 to 2.77) 0.007
   Poorly/un-differentiated 505 92   1.0 2.19 (1.16 to 4.14) 2.23 (1.14 to 4.39) 0.03
Estrogen receptor status        
   Positive 2,233 234 0.83 1.0 1.07 (0.74 to 1.55) 1.59 (1.11 to 2.28) 0.005
   Negative 436 88   1.0 2.07 (1.08 to 3.98) 2.74 (1.44 to 5.19) 0.002
Progesterone receptor status        
   Positive 1,383 87 0.60 1.0 1.83 (0.93 to 3.59) 2.37 (1.23 to 4.58) 0.01
   Negative 787 130   1.0 1.47 (0.88 to 2.47) 2.22 (1.33 to 3.71) 0.002
HER2 status        
   Positive 807 29 0.11 1.0 1.64 (0.34 to 7.96) 8.63 (2.04 to 36.4) <0.001
   Negative 220 19   1.0 1.24 (0.24 to 6.49) 1.29 (0.31 to 5.45) 0.74
  1. Blood samples were drawn and CRP measured at time of diagnosis of breast cancer.
  2. Hazard ratios are multifactor-adjusted for age at diagnosis, tumour size, lymph node status, presence of distant metastases, tumour grade, and estrogen receptor, progesterone receptor, and HER2 status, smoking, alcohol consumption, body mass index, menopause status, and cardiovascular disease (Model 3), excluding the factor stratified for; however, age stratified analyses were still adjusted for age.
  3. Due to differences in numbers of missing values for the covariates in question, numbers of patients and deaths do not necessarily add up to 2,910 and 383, respectively.